Doctors, researchers on quest for a cure News-Herald.com, OH - Nov 28, 2008 For instance, Ireland Cancer Center is researching the use of dendritic cells for fighting brain tumors, Gerson said. Dendritic cells, despite their ...
New Imaging Technique Tracks Cancer-killing Cells Over Prolonged ... Science Daily (press release) - Nov 18, 2008 Gambhir and his colleagues tested the technique in a middle-aged man with an aggressive brain tumor (called a glioblastoma) who was enrolled in a clinical ...
3 siblings diagnosed with rare brain tumor KSL-TV, UT - Nov 13, 2008 Though the gene for this tumor is on the father's side, Steve says, as far as he knows, it hasn't shown up anywhere else. A fund has been set up for the ...
Heroic dog beats cancer after revolutionary treatment WCBD, SC - Nov 26, 2008 ?No one has ever combined gene therapy in the brain for a brain tumor with vaccine.? Immediately after surgery to remove the tumor in August, ...
Brain Tumor Genes Journal of American Medical Association (subscription), IL - Nov 4, 2008 A search of cancer genes has uncovered a number of previously unknown mutations linked to the most common type of adult brain tumor that may help explain ...
UPI NewsTrack Health and Science News United Press International - Nov 28, 2008 The CyberKnife, as the $4 million high-tech machine is called, originally was used to treat hard to reach brain and spinal tumors with radiation. ...
New hope for brain tumors Mirror, MI - Nov 9, 2008 ... are localized treatments for particular brain tumors. These include antibodies to deliver radiation therapy, and possibly viral gene therapy, ...
Source: Google News
Recent News and Articles on the Keywords: tumors + brain + tumor Related to the article below (Last Update: 8/7/2008)
Cancer test patient -- with a wet nose Minneapolis Star Tribune, MN - Or he might have a brain tumor. Only a $1400 MRI could tell them. They faced the dilemma that many pet owners confront. Should they spend thousands for ...
SC political consultant Rod Shealy diagnosed with brain tumor Orangeburg Times Democrat, SC - ... One of South Carolina?s better known bare-knuckles political operatives announced in an online column Tuesday that he has a cancerous brain tumor. ...
Relay for Life helps teen fight own tumor Bloomington Pantagraph, USA - Gary isn?t actually a person; he is a malignant brain tumor. Taylor Gettinger, 16, was diagnosed with it in May 2007. Her mother, Kathleen Gettinger, ...
'Batman' may lead to breakthrough against brain tumors KARE, MN - Aug 5, 2008 Imagine their pain, then, when a series of seizures over the past two weeks led to a diagnosis of a brain tumor. Batman's family was trying to decide what ...
Thomas Bickle: Richardson toddler battled brain tumor Dallas Morning News, TX - Aug 3, 2008 Thomas had battled a brain tumor since he was 6 months old. His fight was reported in The Dallas Morning News in 2006. His mother, Sarah, was a teacher in ...
Albright continues to play Daily Pilot, CA - GOLF: Newport Beach Country Club?s 12-time ladies champion has been dealing with brain tumor for over the past year. By Steve Virgen Not knowing what ...
Source: Google News
National survey of patterns of care for brain-tumor patients. MS Mahaley Jr, C Mettlin, N Natarajan, ER Laws Jr, … - J Neurosurg, 1989 - ncbi.nlm.nih.gov ... An excellent response by participating institutions was realized in this survey
of patterns of care for patients with primary braintumors. ...
WAF1, a potential mediator of p53 tumor suppression. - WS el-Deiry, T Tokino, VE Velculescu, DB Levy, R … - Cell, 1993 - ncbi.nlm.nih.gov ... approach, we identified a gene, named WAF1, whose induction was associated with
wild-type but not mutant p53 gene expression in a human braintumor cell line. ...
PET imaging of brain tumor with [methyl-11C] choline - T Hara - Journal of Nuclear Medicine, 1997 - Soc Nuclear Med ... PET imaging of braintumor with [methyl-11C]choline. ... In patients with braintumor,
PET produced clearly delineated positive images of the tumors. ...
Genes May Influence Response to Brain-Tumor Treatments
Brain tumors with a particular gene composition are more responsive to a specific class of drugs, researchers are reporting.
This knowledge should allow doctors to tailor therapies more appropriately to individual patients, and also open the door to devising new therapies for tumors that have different genetic make-ups.
The specific tumors in question are glioblastomas, a difficult-to-treat, aggressive form of cancer with a low survival rate.
"A subset of patients are more likely to respond, and by understanding why other subsets are failing, we can begin to think about customizing combinations of therapies to help treat those" patients, said Dr. Paul Mischel, senior author of the study that appears in the Nov. 10 issue of the New England Journal of Medicine.
"This drives a wedge into the dirt and begins to expose the possibility of figuring out what is really happening in patients who aren’t responding," added Mischel, a researcher at the David Geffen School of Medicine and Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.
The findings may lead to an immediate shift in how brain-tumor treatments are directed.
"We already are starting to change the way we look at treatments and narrow down the treatments we give to patients," said Dr. Susan Pannullo, director of neuro-oncology at New York Presbyterian Hospital-Weill Cornell Medical College in New York City. "This data is very important because there is so little that works right now."
Two drugs, Tarceva (erlotinib) and Iressa (gefitinib), have had some success in treating glioblastomas and have been approved for treating advanced lung cancer that has not responded to other treatments, the study authors said.
Both drugs belong to a class of medications called EGFR (epidermal growth factor receptor) kinase inhibitors. The EGFR gene is frequently dysfunctional in glioblastomas, yet only 10 percent to 20 percent of patients with this type of tumor respond to Iressa or Tarceva.
As an accompanying editorial in the journal pointed out, there seems to be no correlation between a patient’s response to the drugs and the function of EGFR. The drugs were obviously affecting a different mutation in patients with glioblastoma.
The question was, which one? Glioblastomas exhibit abnormal activity in a number of genes, including the EGFR gene, and the loss of PTEN, a tumor-suppressor protein.
"We hypothesized that two proteins, EGFRvIII [a variant of EGFR] and PTEN played a critical role and thus their interaction might be important for developing a response" to Tarceva and Iressa, Mischel explained.
To test the hypothesis, Mischel and his colleagues performed a genetic analysis of tissue from 26 glioblastoma patients who had either clearly responded or clearly failed to respond to Tarceva or Iressa.
As it turned out, glioblastomas that produced both EGFRvIII and PTEN were 51 times more likely to shrink when treated with one of these drugs than tumors with different genetic makeups. And patients also went five times longer (243 days versus 50 days) before their tumors progressed.
The results were verified in tissues from another group of patients who had participated in a clinical trial of Tarceva.
Although the prognosis is still poor for these patients, Pannullo said, these results may represent a big step toward eventually finding a cure.
"We’re beginning to understand that there’s much more to predicting what kinds of treatments a particular tumor might respond to than just what we can figure out from looking at traditional pathology specimen," Pannullo said. "This study, along with another one, really shows that there is hope that looking at genetics may help to improve the way that we treat these patients."
